Switch theme
Sign up to access all valuation multiples
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
2000
n/a
LTM Revenue $570M
LTM EBITDA $97.6M
$7.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Haisco Pharmaceutical has a last 12-month revenue (LTM) of $570M and a last 12-month EBITDA of $97.6M.
In the most recent fiscal year, Haisco Pharmaceutical achieved revenue of $517M and an EBITDA of $104M.
Haisco Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Haisco Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $570M | XXX | $517M | XXX | XXX | XXX |
| Gross Profit | $414M | XXX | $369M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $97.6M | XXX | $104M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $81.3M | XXX | $63.7M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $66.4M | XXX | $54.9M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $15.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Haisco Pharmaceutical's stock price is CNY 46 (or $6).
Haisco Pharmaceutical has current market cap of CNY 51.3B (or $7.1B), and EV of CNY 52.2B (or $7.2B).
See Haisco Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.2B | $7.1B | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Haisco Pharmaceutical has market cap of $7.1B and EV of $7.2B.
Haisco Pharmaceutical's trades at 14.0x EV/Revenue multiple, and 69.6x EV/EBITDA.
Equity research analysts estimate Haisco Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Haisco Pharmaceutical has a P/E ratio of 107.2x.
See valuation multiples for Haisco Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.1B | XXX | $7.1B | XXX | XXX | XXX |
| EV (current) | $7.2B | XXX | $7.2B | XXX | XXX | XXX |
| EV/Revenue | 12.7x | XXX | 14.0x | XXX | XXX | XXX |
| EV/EBITDA | 74.2x | XXX | 69.6x | XXX | XXX | XXX |
| EV/EBIT | 89.2x | XXX | 113.6x | XXX | XXX | XXX |
| EV/Gross Profit | 17.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 107.2x | XXX | 129.7x | XXX | XXX | XXX |
| EV/FCF | 12516.5x | XXX | 37518.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHaisco Pharmaceutical's last 12 month revenue growth is 21%
Haisco Pharmaceutical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Haisco Pharmaceutical's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Haisco Pharmaceutical's rule of X is 71% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Haisco Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 38% | XXX | 24% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 71% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Haisco Pharmaceutical acquired XXX companies to date.
Last acquisition by Haisco Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Haisco Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Haisco Pharmaceutical founded? | Haisco Pharmaceutical was founded in 2000. |
| Where is Haisco Pharmaceutical headquartered? | Haisco Pharmaceutical is headquartered in China. |
| Is Haisco Pharmaceutical publicy listed? | Yes, Haisco Pharmaceutical is a public company listed on SHE. |
| What is the stock symbol of Haisco Pharmaceutical? | Haisco Pharmaceutical trades under 002653 ticker. |
| When did Haisco Pharmaceutical go public? | Haisco Pharmaceutical went public in 2012. |
| Who are competitors of Haisco Pharmaceutical? | Similar companies to Haisco Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Haisco Pharmaceutical? | Haisco Pharmaceutical's current market cap is $7.1B |
| What is the current revenue of Haisco Pharmaceutical? | Haisco Pharmaceutical's last 12 months revenue is $570M. |
| What is the current revenue growth of Haisco Pharmaceutical? | Haisco Pharmaceutical revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Haisco Pharmaceutical? | Current revenue multiple of Haisco Pharmaceutical is 12.7x. |
| Is Haisco Pharmaceutical profitable? | Yes, Haisco Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Haisco Pharmaceutical? | Haisco Pharmaceutical's last 12 months EBITDA is $97.6M. |
| What is Haisco Pharmaceutical's EBITDA margin? | Haisco Pharmaceutical's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Haisco Pharmaceutical? | Current EBITDA multiple of Haisco Pharmaceutical is 74.2x. |
| What is the current FCF of Haisco Pharmaceutical? | Haisco Pharmaceutical's last 12 months FCF is $0.6M. |
| What is Haisco Pharmaceutical's FCF margin? | Haisco Pharmaceutical's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Haisco Pharmaceutical? | Current FCF multiple of Haisco Pharmaceutical is 12516.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
